Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $118.8 million.

  • Allogene Therapeutics' Total Non-Current Liabilities fell 7.42% to $109.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.0 million, marking a year-over-year decrease of 7.42%. This contributed to the annual value of $118.8 million for FY2024, which is 5.31% down from last year.
  • Per Allogene Therapeutics' latest filing, its Total Non-Current Liabilities stood at $118.8 million for FY2024, which was down 5.31% from $125.4 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Total Non-Current Liabilities registered a high of $148.8 million during FY2022, and its lowest value of $117.8 million during FY2021.
  • Over the past 3 years, Allogene Therapeutics' median Total Non-Current Liabilities value was $125.4 million (recorded in 2023), while the average stood at $131.0 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Total Non-Current Liabilities spiked by 71.90% in 2020, and later decreased by 18.81% in 2021.
  • Over the past 5 years, Allogene Therapeutics' Total Non-Current Liabilities (Yearly) stood at $145.1 million in 2020, then decreased by 18.81% to $117.8 million in 2021, then grew by 26.32% to $148.8 million in 2022, then decreased by 15.74% to $125.4 million in 2023, then fell by 5.31% to $118.8 million in 2024.